Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that data being presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) demonstrate that patients treated with DIFICID™ (fidaxomicin) tablets for Clostridium difficile-associated diarrhea (CDAD) experienced faster resolution of diarrhea and lower risk of death during the first 12 days following initiation of treatment compared to patients treated with vancomycin. The retrospective analysis of results from two large, multi-national Phase 3 clinical studies, which assessed the efficacy of DIFICID versus vancomycin for the treatment of CDAD in adults, was completed by researchers from the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford,  a research partnership between the Oxford Radcliffe Hospitals and the University of Oxford.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

In the analysis, patients treated with DIFICID experienced a 37% reduction in persistent diarrhea or death through day 12 of the study (95% CI: 2-60%; p=0.037) compared to those treated with vancomycin. These data are among those featured in a late-breaking poster presentation at the IDSA annual meeting being held in Boston from October 20-23.

"We were encouraged by the results of the Phase 3 clinical studies and believed that a more comprehensive look at the patient characteristics of the Phase 3 study participants might yield even greater insights into the use of DIFICID for the treatment of CDAD," said Sarah Walker, PhD, Senior Statistician at the NIHR Biomedical Research Centre, Oxford, and the primary author of the analysis. "In our analysis, we found that DIFICID not only reduced persistent diarrhea and early death
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... CUPERTINO, Calif. , March 30, 2015 /PRNewswire/ ... announced that it has initiated a multi-dose Phase ... DUR-928, the lead molecule in DURECT,s Epigenomic Regulator ... entity (NCE) that may have broad applicability in ... (NAFLD) and nonalcoholic steatohepatitis (NASH).  It may also ...
(Date:3/30/2015)... Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) ... to the position of Executive Vice President & ... be responsible for all legal, compliance and intellectual property ... BioDelivery Sciences International, Inc., where he was Senior Vice ... management that led that company to over a six ...
(Date:3/30/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... the investment community and media on the company,s diabetes ... 75th American Diabetes Association® Scientific Sessions, will include multiple ... review of the Phase III data for basal insulin ... The meeting will be held from 7-8:30 ...
Breaking Medicine Technology:DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Lilly Announces Date for Diabetes Investor Meeting 2
... ABBOTT PARK, Ill., Feb. 8 A new diagnostic ... form of ovarian cancer may soon be available in the ... simple blood test to help in monitoring for the recurrence or ... be the first automated HE4 test available in the United ...
... HAYWARD, Calif. , Feb. 8 Anthera ... treat serious diseases associated with inflammation, announced today that it ... (FDA) on a Special Protocol Assessment (SPA) for the Phase ... Acute Coronary Syndrome - 16 Weeks) for its lead product ...
Cached Medicine Technology:Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval 2Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval 3Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors 2Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors 3
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... “6 New Ways to Blast Away Fat,” details six new ... these treatments require injections and one is a topical product. ... ( UltraShape and Liposonix ) or freezing cold ... “There are so many options now available to us to ...
(Date:3/30/2015)... 30, 2015 In a recent report ... Governor Chris Christie is championing effective drug and alcohol ... is scrambling to recover funds to stabilize the addiction ... for victims of drug and alcohol addiction. Harbor Village ... plagued by substance use disorders in New Jersey, in ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... 2015 Dr. Daniel Shapiro, one of the ... recently featured on Phoenix’s Channel 12 News about the benefits ... minimally invasive alternative to facelifts developed by Dr. Shapiro. , ... at Shapiro Aesthetic Plastic Surgery and Skin Klinic worked closely ... news story on GenXLift. The story detailed the experience and ...
(Date:3/30/2015)... GenSight ®, provider of an Enterprise Portfolio Management ... Forrester Wave™: Strategic Planning For The [Business Technology] BT ... GenSight as a leader and gave the company the ... analytics, corporate strategy, assessment, direction and life cycle support ... Leaders category. , According to the report: GenSight ...
Breaking Medicine News(10 mins):Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Dr. Daniel Shapiro Unveils New Minimally Invasive Facelift Procedure on Local Newscast 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3
... never make it big in Hollywood as she feels she is too ... short impedes her. She says: I don't think that's ever going to ... tend to look really small on camera. ,'I can probably ... to be it. I have a feeling I am way too small.' ...
... workers who were abducted by Taliban at gunpoint were ... that they were all health workers. // They abduction ... militants snatched on Thursday a vehicle carrying the 15 ... after their identity was made clear, Outlook newspaper quoted ...
... like angioplasty are the various treatments for people ... is a small industrial city in northeast Ohio. ... the country, would suggest their patients to go ... balloon catheters through arteries and sometimes placing drug-coated ...
... Nepal have irked student organizations who came out on the ... roads and stoned vehicles and burnt tyres on the streets. ... population of Nepal is furious with the price hike, which ... student wings of two of the leading parties in the ...
... reports of moderate iodine deficiency among New Zealanders and ... the Trans-Tasman regulator// Food Standards Australia New Zealand (FSANZ) ... iodized salt in some common household products. Recent ... not getting enough of iodine. ,The proposal by ...
... Scientists have achieved a very important milestone in the mapping ... enhance the health and aid better disease// control in cattle. ... industry immensely. ,Scientists firmed up on a sequence ... the value of the difference even in one pair, which ...
Cached Medicine News:Health News:Heart Procedure numbers go haywire in an Ohio City 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 3
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 0.5-10 microliter range....
Medicine Products: